Samuel Murphy
Chief Executive Officer Salubris Biotherapeutics Inc.
Sam is currently CEO of SalubrisBio and has worked at SalubrisBio since 2017. Prior to joining SalubrisBio, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, and a Board Observer at Mercator Medsystems. Sam was previously Board Director at MedAlliance SA (acquired for up to $1.1B by Cordis) and Viracta Therapeutics (public by reverse merger VIRX). He is an author of >20 peer-reviewed publications and an inventor on several issued patents.
Seminars
- Outlining the developing clinical profile of JK06 from dose escalation to Phase I/II expansion cohort data
- Contextualizing the maturing clinical profile of JK06 across efficacy and safety profile in lung and breast cancer cohorts
- Explaining the differentiated clinical impact of JK06 through dual epitope binding and site specific conjugation for a novel ADC activity and safety profile
